DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.11B
AUM Growth
+$3.11B
(+0.72%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-4.82%
Top 10 Holdings %
Top 10 Hldgs %
52.57%
Holding
75
New
6
Increased
18
Reduced
21
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$150M |
| 2 |
Axsome Therapeutics
AXSM
|
$83.7M |
| 3 |
Vaxcyte
PCVX
|
$45.5M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$34.6M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$25.1M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$264M |
| 2 |
BridgeBio Pharma
BBIO
|
$82M |
| 3 |
Guardant Health
GH
|
$62.1M |
| 4 |
RAPT Therapeutics
RAPT
|
$42.1M |
| 5 |
Amgen
AMGN
|
$35.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Context Therapeutics
CNTX
$75.4M
| $4.86M | 0.16% |
7,419,355
| – | – |
|
52
Pliant Therapeutics
PLRX
$101M
| $4.58M | 0.15% |
3,947,807
-1,451,874
| -27% | -$1.68M |
|
53
Sarepta Therapeutics
SRPT
$1.78B
| $4.44M | 0.14% |
259,800
-639,931
| -71% | -$10.9M |
|
54
Xencor
XNCR
$580M
| $4.32M | 0.14% |
549,439
| – | – |
|
55
Inovio Pharmaceuticals
INO
$126M
| $4.03M | 0.13% |
1,981,370
-1,137,792
| -36% | -$2.32M |
|
56
Korro Bio
KRRO
$217M
| $3.47M | 0.11% |
277,966
-596,648
| -68% | -$7.45M |
|
|
IMA
57
ImageneBio, Inc. Common Stock
IMA
$150M
| $3.37M | 0.11% |
2,515,513
| – | – |
|
58
Spyre Therapeutics
SYRE
$996M
| $3.28M | 0.11% |
219,015
| – | – |
|
59
Aligos Therapeutics
ALGS
$73.3M
| $3.2M | 0.1% |
444,110
| – | – |
|
60
Avalo Therapeutics
AVTX
$122M
| $2.83M | 0.09% |
567,103
-292,773
| -34% | -$1.46M |
|
61
Zura Bio
ZURA
$133M
| $1.81M | 0.06% |
1,727,562
-1,556,221
| -47% | -$1.63M |
|
|
CLYM
62
Climb Bio, Inc. Common Stock
CLYM
$151M
| $1.29M | 0.04% |
1,040,115
| – | – |
|
|
SEPN
63
Septerna, Inc. Common Stock
SEPN
$539M
| $1.29M | 0.04% |
121,716
-1,791,213
| -94% | -$18.9M |
|
|
RAPP
64
Rapport Therapeutics
RAPP
$643M
| $1.12M | 0.04% |
98,237
-359,319
| -79% | -$4.09M |
|
|
OKUR
65
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $431K | 0.01% |
180,510
-343,479
| -66% | -$821K |
|
|
ALLK
66
DELISTED
Allakos
ALLK
| – | – |
-7,232,701
| Closed | -$1.65M |
|
|
67
Amgen
AMGN
$155B
| – | – |
-113,035
| Closed | -$35.2M |
|
68
Beam Therapeutics
BEAM
$1.66B
| – | – |
-315,765
| Closed | -$6.17M |
|
69
Dyne Therapeutics
DYN
$1.92B
| – | – |
-2,000,000
| Closed | -$20.9M |
|
70
Edgewise Therapeutics
EWTX
$1.51B
| – | – |
-1,400,000
| Closed | -$30.8M |
|
71
Galapagos
GLPG
$2.07B
| – | – |
-741,068
| Closed | -$18.6M |
|
72
Neurogene
NGNE
$264M
| – | – |
-116,660
| Closed | -$1.37M |
|
|
RGLS
73
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-3,262,564
| Closed | -$5.71M |
|
|
SAGE
74
DELISTED
Sage Therapeutics
SAGE
| – | – |
-2,038,845
| Closed | -$16.2M |
|
|
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-2,000,000
| Closed | -$264M |
|